Intra-Cellular Therapies

Intra-Cellular Therapies is a commercial-stage biopharma company that transitioned from an independent entity to a subsidiary of Johnson & Johnson, significantly bolstering its resources and commercial reach. The company's core approach is based on pioneering intracellular research, which it applies to develop novel therapeutics for underserved mental health and neurological conditions. Its lead asset, CAPLYTA, is an FDA-approved treatment for schizophrenia and bipolar depression, representing a validated commercial product. The company's integration into J&J provides a powerful platform for lifecycle management of its approved drug and advancement of its broader pipeline.

Drug discovery platform based on Nobel Prize-winning research into intracellular signaling pathways, focusing on how therapies affect inner-cell workings to develop novel small molecules for complex CNS disorders.

CAPLYTA competes in the crowded antipsychotic market for schizophrenia and the growing market for bipolar depression, facing competition from both other atypical antipsychotics (e.g., aripiprazole, quetiapine, lurasidone) and emerging modalities. Its key differentiator is a tolerability profile aimed at minimizing metabolic and neurological side effects.